Translation Google
Mpox in Germany
Status: October 22, 2024Due to an increase in Mpox in 2024 in several African countries caused by Mpox clade I viruses, the WHO declared a public health emergency of international concern (PHEIC) for Mpox on August 14, 2024. Declaring a PHEIC enables affected countries to take or intensify further measures , e.g. with regard to vaccine availability, the expansion of diagnostic capacities and other public health measures.
The occurrence of Mpox in Germany to date is primarily related to an Mpox event that has affected many countries worldwide since May 2022 and is caused by Mpox viruses of clade IIb. On October 18, 2024, an Mpox infection caused by the new clade Ib that was acquired abroad was detected in Germany (see below). Close physical contact is required for Mpox to be transmitted. For transmission and prevention options, see www.rki.de/mpox-flyer and the RKI guide to Mpox . The RKI currently considers the risk to the health of the general population in Germany to be low. The RKI continues to monitor the situation closely and, if necessary, adapts its assessment to the current state of knowledge.
Clade I
Since 2023, the WHO has reported an increase in infections with Mpox clade I (including a new variant Ib) in Africa, particularly in the Democratic Republic of Congo (see FAQ on Mpox www.rki.de/mpox-faq > What is known about Mpox clade I outbreaks in Africa? ). The European Center for Disease Prevention and Control has published a comprehensive risk assessment (16.8.2024) and currently classifies the risk of variant Ib for the population in Europe as "low" overall. In Germany, one Mpox infection caused by clade Ib has so far been detected, which was acquired abroad. The RKI currently still does not assume an increased risk from clade I viruses in Germany, but is monitoring the situation very closely and adapting its recommendations if necessary. Information on prevention options, medical care and recommendations for the public health service can be found in the RKI guide to Mpox . There are initially no other measures for medical care. Potential implications for public health recommendations are currently being assessed. It is assumed that available vaccines are also effective against clade I.
Clade IIb
In Germany, cases of Mpox clade IIb were identified for the first time in May 2022. To date, around 3,800 cases have been reported to the RKI, the majority of them (around 3,700 cases) from early summer to autumn 2022. After a sharp increase from May 2022, the number of cases has fallen significantly from August 2022 as a result of intensive public health efforts by various agencies. Since mid-October 2022, only a few cases have been reported. After initially no cases were registered at all in spring 2023, case numbers have been continuously reported at a low level (in the single to low double-digit range per month) since summer 2023. No deaths have been registered in Germany so far. Case numbers by reporting week, country, district, age group and gender are available daily via SurvStat https://survstat.rki.de . In this country, transmissions of Mpox clade IIb have primarily occurred in the context of sexual activities, especially among men who have sexual contact with other men (less than 1% of cases affect women, adolescents or children).
Clade II Mpox cases are still being reported to the RKI. A limited outbreak is also possible again, but a sharp increase in the number of cases like in 2022 is not currently expected. Information on prevention options, medical care and recommendations for the public health service can be found in the RKI guide to Mpox .
Most of those affected do not become seriously ill. Worldwide, more than 100,000 cases have been reported to the WHO as part of the Mpox clade IIb outbreak , including over 200 deaths . Current international case numbers can be found on the WHO dashboard and Mpox outbreak page . The WHO continues to emphasize the importance of surveillance and prevention measures as well as intensive research.
Further information from the RKI
At www.rki.de/mpox, the RKI provides the RKI guide to Mpox , answers to frequently asked questions (FAQs) about Mpox and various recommendations and information on hygiene measures, procedures for large events, diagnostics and therapy, among other things. A flyer from the RKI and BZgA with information on transmission routes and prevention options, among other things, is available at www.rki-de/mpox-flyer .
A flow chart for the clarification of suspected cases and necessary measures is provided as a guide for doctors . If there are questions about clinical management in special disease courses, the RKI and STAKOB (Permanent Working Group of Competence and Treatment Centers for Diseases Caused by Highly Pathogenic Agents) offer the professional public a 24/7 consultation service . Specialized laboratories such as the consulting laboratory for smallpox viruses can diagnose all occurring variants of clades I and II.
Information on vaccination against Mpox , including the STIKO vaccination recommendation and vaccination FAQs , can be found at www.rki.de/mpox-impfung .
Status: October 22, 2024
https://www.rki.de/DE/Content/InfAZ/...utschland.html
Mpox in Germany
Status: October 22, 2024Due to an increase in Mpox in 2024 in several African countries caused by Mpox clade I viruses, the WHO declared a public health emergency of international concern (PHEIC) for Mpox on August 14, 2024. Declaring a PHEIC enables affected countries to take or intensify further measures , e.g. with regard to vaccine availability, the expansion of diagnostic capacities and other public health measures.
The occurrence of Mpox in Germany to date is primarily related to an Mpox event that has affected many countries worldwide since May 2022 and is caused by Mpox viruses of clade IIb. On October 18, 2024, an Mpox infection caused by the new clade Ib that was acquired abroad was detected in Germany (see below). Close physical contact is required for Mpox to be transmitted. For transmission and prevention options, see www.rki.de/mpox-flyer and the RKI guide to Mpox . The RKI currently considers the risk to the health of the general population in Germany to be low. The RKI continues to monitor the situation closely and, if necessary, adapts its assessment to the current state of knowledge.
Clade I
Since 2023, the WHO has reported an increase in infections with Mpox clade I (including a new variant Ib) in Africa, particularly in the Democratic Republic of Congo (see FAQ on Mpox www.rki.de/mpox-faq > What is known about Mpox clade I outbreaks in Africa? ). The European Center for Disease Prevention and Control has published a comprehensive risk assessment (16.8.2024) and currently classifies the risk of variant Ib for the population in Europe as "low" overall. In Germany, one Mpox infection caused by clade Ib has so far been detected, which was acquired abroad. The RKI currently still does not assume an increased risk from clade I viruses in Germany, but is monitoring the situation very closely and adapting its recommendations if necessary. Information on prevention options, medical care and recommendations for the public health service can be found in the RKI guide to Mpox . There are initially no other measures for medical care. Potential implications for public health recommendations are currently being assessed. It is assumed that available vaccines are also effective against clade I.
Clade IIb
In Germany, cases of Mpox clade IIb were identified for the first time in May 2022. To date, around 3,800 cases have been reported to the RKI, the majority of them (around 3,700 cases) from early summer to autumn 2022. After a sharp increase from May 2022, the number of cases has fallen significantly from August 2022 as a result of intensive public health efforts by various agencies. Since mid-October 2022, only a few cases have been reported. After initially no cases were registered at all in spring 2023, case numbers have been continuously reported at a low level (in the single to low double-digit range per month) since summer 2023. No deaths have been registered in Germany so far. Case numbers by reporting week, country, district, age group and gender are available daily via SurvStat https://survstat.rki.de . In this country, transmissions of Mpox clade IIb have primarily occurred in the context of sexual activities, especially among men who have sexual contact with other men (less than 1% of cases affect women, adolescents or children).
Clade II Mpox cases are still being reported to the RKI. A limited outbreak is also possible again, but a sharp increase in the number of cases like in 2022 is not currently expected. Information on prevention options, medical care and recommendations for the public health service can be found in the RKI guide to Mpox .
Most of those affected do not become seriously ill. Worldwide, more than 100,000 cases have been reported to the WHO as part of the Mpox clade IIb outbreak , including over 200 deaths . Current international case numbers can be found on the WHO dashboard and Mpox outbreak page . The WHO continues to emphasize the importance of surveillance and prevention measures as well as intensive research.
Further information from the RKI
At www.rki.de/mpox, the RKI provides the RKI guide to Mpox , answers to frequently asked questions (FAQs) about Mpox and various recommendations and information on hygiene measures, procedures for large events, diagnostics and therapy, among other things. A flyer from the RKI and BZgA with information on transmission routes and prevention options, among other things, is available at www.rki-de/mpox-flyer .
A flow chart for the clarification of suspected cases and necessary measures is provided as a guide for doctors . If there are questions about clinical management in special disease courses, the RKI and STAKOB (Permanent Working Group of Competence and Treatment Centers for Diseases Caused by Highly Pathogenic Agents) offer the professional public a 24/7 consultation service . Specialized laboratories such as the consulting laboratory for smallpox viruses can diagnose all occurring variants of clades I and II.
Information on vaccination against Mpox , including the STIKO vaccination recommendation and vaccination FAQs , can be found at www.rki.de/mpox-impfung .
Status: October 22, 2024
https://www.rki.de/DE/Content/InfAZ/...utschland.html
Comment